Disli, Zeliha KorkmazDelen, Leman AcunTas, Hakan GokalpKuyrukluyildiz, UfukDisli, Olcay MuratYazici, Gulce NazCoban, Abdulkadir2024-08-042024-08-0420220326-2383https://hdl.handle.net/11616/100563The metabolite of desflurane has been linked to hepatotoxicity. Carvacrol possesses antioxidant, antibacterial, antifungal, anticancer, anti-inflammatory, and spasmolytic properties, according to research. Our goal is to demonstrate that carvacrol protects rats' livers against repeated doses of desflurane. Healthy (HG), desflurane (DS), and carvacrol + desflurane treatment (CDS) groups were formed from 18 albino male Wistar rats. A single dosage of carvacrol and 6% desflurane was given for 2 h on the 0th and 8th days. In the CDS group, the ALT and AST, MDA, TOS, NF-xB, TNF-alpha IL1 beta levels were lower compared to the DS group (p < 0.001). The tGSH,TAS levels were found to be higher in the CDS group compared to the DS group (p < 0.001). It was determined that the mean degeneration level, Kupffer cell activation and PMNL infiltration were found to be lower compared to the DS group (p < 0.05).We confirmed that carvacol can be used in the treatment of desflurane-related liver injury.eninfo:eu-repo/semantics/closedAccessantioxidantcarvacroldesfluranehepatotoxicityinhalation anesthesiaArticle4111301372-s2.0-85127149965Q4WOS:000747919200002Q4